Lung cancer is still a main cause of cancer-related death worldwide. Non-small-cell lung
cancer (NSCLC) accounts for the majority of lung cancers, and gefitinib is an effective …

Background This study investigated the role of fibrinogen-like protein 1 (FGL1) in regulating
gefitinib resistance of PC9/GR non-small cell lung cancer (NSCLC). Methods The effect of …

Background. Gefitinib resistance remains a major problem in the treatment of lung cancer.
However, the underlying mechanisms involved in gefitinib resistance are largely unclear …

Integrin β3 plays a key role in the resistance to epidermal growth factor receptor tyrosine
kinase inhibitors (EGFR-TKI), but the development of integrin β3 inhibitors has been stalled …

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-
TKIs), such as gefitinib, has dramatically impaired the clinical outcomes in non-small cell …

Background Gefitinib-resistance is a primary obstacle for the treatment of non-small-cell lung
cancer (NSCLC). It has been shown that tanshinone IIA (Tan IIA) could induce apoptosis of …

There is a paucity of comprehensive knowledge pertaining to the underlying mechanisms
leading to gefitinib resistance in individuals diagnosed NSCLC harboring EGFR-sensitive …

Background Acquired resistance to epidermal growth factor receptor tyrosine kinase
inhibitors (EGFR-TKIs) presents great challenges in the treatment of non-small cell lung …

The epidermal growth factor receptor-tyrosine kinase inhibitors (EGFRTKI), such as gefitinib
and erlotinib have improved the survival of patients with nonsmall cell lung cancer (NSCLC) …

Filamin A (FLNa) is a ubiquitously expressed cytoplasmic protein, which composes of an N-
terminal actin binding domain (ABD) followed by 24 Ig-like repeats. FLNa functions as a …